Petros Pharmaceuticals, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2022 | $-5.3M | $-5.3M | — | $355.8K |
| Jun 2022 | $-4.2M | $-4.2M | — | $302.3K |
| Sep 2022 | $-1.8M | $-1.8M | — | $308.1K |
| Dec 2022 | $-1.6M | $-1.6M | — | $228.8K |
| Mar 2023 | $-748.4K | $-748.4K | — | $130.3K |
| Jun 2023 | $-572.1K | $-572.1K | — | $43.3K |
| Sep 2023 | $-4.0M | $-4.0M | — | $30.8K |
| Dec 2023 | $-2.3M | $-2.3M | — | $212.7K |
| Mar 2024 | $-1.1M | $-1.1M | — | — |
| Jun 2024 | $-1.7M | $-1.7M | — | — |
| Sep 2024 | $-771.2K | $-771.2K | — | — |
| Dec 2024 | $965.4K | $965.4K | — | — |
| Mar 2025 | $-1.7M | $-1.7M | — | $80.0K |
| Jun 2025 | $-3.0M | $-3.0M | — | $74.3K |
| Sep 2025 | $-1.1M | $-1.1M | — | — |
| Dec 2025 | $-933.5K | $-933.5K | — | — |
| Mar 2026 | $-784.3K | $-784.3K | — | $120.3K |
| Jun 2026 | $-863.9K | $-863.9K | — | $117.9K |